Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIZE: Reduced Dose Post-Transplant Cyclophosphamide for GvHD Prophylaxis in Hematologic Malignancies
NCT06001385Phase 2Active, not recruiting
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Center for International Blood and Marrow Transplant Research. Started Dec 2023; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06001385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001385.